Name
As of 03/26/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
4.9%
1 yr return
12.0%
3 Yr Avg Return
6.1%
5 Yr Avg Return
9.1%
Net Assets
$11.5 M
Holdings in Top 10
44.5%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 2.35%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 19.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$250
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 03/26/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
SBHIX - Profile
Distributions
- YTD Total Return 4.9%
- 3 Yr Annualized Total Return 6.1%
- 5 Yr Annualized Total Return 9.1%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.69%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameHealth & Biotechnology Portfolio
-
Fund Family NameSaratoga Advantage Trust
-
Inception DateJan 27, 2003
-
Shares OutstandingN/A
-
Share ClassI
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerRobert Stimpson
Fund Description
The Portfolio will normally invest at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or “market capitalization”). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. The Adviser utilizes a top-down investment approach focused on long-term economic trends. The Adviser begins with the overall outlook for the economy, then seeks to identify specific industries with attractive characteristics and long-term growth potential. Ultimately, the Adviser seeks to identify high-quality companies within the selected industries and to acquire them at attractive prices. The Adviser’s stock selection process is based on an analysis of individual companies’ fundamental values, such as earnings growth potential and the quality of corporate management.
Companies described as Health Care Equipment and Supplies, Health Care Provider Services, Pharmaceutical or Biotechnology Companies under the North American Industry Classification System are considered healthcare or biotechnology companies for purposes of investment by the Portfolio. These companies are principally engaged in: the design, manufacture or sale of products or services used for or in connection with health, medical, or personal care such as medical, dental and optical supplies or equipment; research and development of pharmaceutical products and services; the operation of healthcare facilities such as hospitals, clinical test laboratories and convalescent and mental healthcare facilities; and the design, manufacture, or sale of healthcare-related products and services, research, development, manufacture or distribution of products and services relating to human health care, pharmaceuticals, agricultural and veterinary applications and the environment; and manufacturing and/or distributing biotechnological and biomedical products, devices or instruments or provide materials, products or services to the foregoing companies.
Factors considered include growth potential, earnings, valuation, competitive advantages and management. When market or financial conditions warrant, the Portfolio may also make temporary investments in investment grade debt securities. Such investment strategies could result in the Portfolio not achieving its investment objective.
SBHIX - Performance
Return Ranking - Trailing
Period | SBHIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | 4.9% | -13.0% | 22.1% | 74.85% |
1 Yr | 12.0% | -19.6% | 37.7% | 69.94% |
3 Yr | 6.1%* | -30.2% | 13.9% | 26.92% |
5 Yr | 9.1%* | -2.8% | 14.5% | 52.94% |
10 Yr | 7.3%* | 0.3% | 14.3% | 73.83% |
* Annualized
Return Ranking - Calendar
Period | SBHIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | -4.4% | -12.6% | 19.0% | 88.96% |
2022 | -2.7% | -53.9% | 3.2% | 3.21% |
2021 | 13.3% | -39.6% | 24.2% | 13.46% |
2020 | -7.4% | -13.6% | 178.2% | 98.68% |
2019 | 12.2% | 3.8% | 63.8% | 92.59% |
Total Return Ranking - Trailing
Period | SBHIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | 4.9% | -13.0% | 22.1% | 74.85% |
1 Yr | 12.0% | -19.6% | 37.7% | 69.94% |
3 Yr | 6.1%* | -30.2% | 13.9% | 26.92% |
5 Yr | 9.1%* | -2.8% | 14.5% | 52.94% |
10 Yr | 7.3%* | 0.3% | 14.3% | 73.83% |
* Annualized
Total Return Ranking - Calendar
Period | SBHIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | 0.0% | -12.6% | 19.0% | 82.21% |
2022 | 2.4% | -53.9% | 3.7% | 2.56% |
2021 | 17.2% | -33.9% | 26.0% | 19.87% |
2020 | 4.0% | -0.7% | 180.6% | 97.35% |
2019 | 21.1% | 4.6% | 63.8% | 82.96% |
NAV & Total Return History
SBHIX - Holdings
Concentration Analysis
SBHIX | Category Low | Category High | SBHIX % Rank | |
---|---|---|---|---|
Net Assets | 11.5 M | 6.16 M | 45 B | 88.34% |
Number of Holdings | 34 | 23 | 413 | 92.02% |
Net Assets in Top 10 | 5.15 M | 2.07 M | 20.4 B | 84.66% |
Weighting of Top 10 | 44.46% | 18.1% | 77.0% | 57.67% |
Top 10 Holdings
- AMGEN INC 5.56%
- REGENERON PHARM 5.13%
- CENCORA INC 4.68%
- MCKESSON CORP 4.68%
- CARDINAL HEALTH 4.60%
- UNITEDHEALTH GRP 4.30%
- HUMANA INC 4.05%
- VERTEX PHARM 3.86%
- INTUITIVE SURGIC 3.82%
- ENSIGN GROUP INC 3.79%
Asset Allocation
Weighting | Return Low | Return High | SBHIX % Rank | |
---|---|---|---|---|
Stocks | 99.34% | 87.17% | 106.13% | 30.67% |
Cash | 1.01% | 0.00% | 32.99% | 60.12% |
Preferred Stocks | 0.00% | 0.00% | 7.86% | 31.90% |
Other | 0.00% | -22.99% | 17.73% | 34.97% |
Convertible Bonds | 0.00% | 0.00% | 0.37% | 9.49% |
Bonds | 0.00% | 0.00% | 12.39% | 14.72% |
Stock Sector Breakdown
Weighting | Return Low | Return High | SBHIX % Rank | |
---|---|---|---|---|
Healthcare | 100.00% | 59.26% | 100.00% | 1.27% |
Utilities | 0.00% | 0.00% | 0.00% | 1.90% |
Technology | 0.00% | 0.00% | 22.69% | 8.86% |
Real Estate | 0.00% | 0.00% | 5.89% | 5.70% |
Industrials | 0.00% | 0.00% | 7.02% | 7.59% |
Financial Services | 0.00% | 0.00% | 1.60% | 28.48% |
Energy | 0.00% | 0.00% | 0.00% | 1.90% |
Communication Services | 0.00% | 0.00% | 9.11% | 5.06% |
Consumer Defense | 0.00% | 0.00% | 25.73% | 13.29% |
Consumer Cyclical | 0.00% | 0.00% | 1.92% | 7.59% |
Basic Materials | 0.00% | 0.00% | 7.16% | 33.54% |
Stock Geographic Breakdown
Weighting | Return Low | Return High | SBHIX % Rank | |
---|---|---|---|---|
US | 99.34% | 66.21% | 104.41% | 17.79% |
Non US | 0.00% | 0.00% | 29.78% | 56.44% |
SBHIX - Expenses
Operational Fees
SBHIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 2.35% | 0.08% | 4.28% | 13.50% |
Management Fee | 1.25% | 0.03% | 1.25% | 97.55% |
12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
Administrative Fee | N/A | 0.03% | 0.25% | 60.00% |
Sales Fees
SBHIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | N/A | 3.50% | 5.75% | N/A |
Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
SBHIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 1.00% | 1.00% | 16.67% |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
SBHIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | 19.00% | 0.00% | 238.00% | 12.32% |
SBHIX - Distributions
Dividend Yield Analysis
SBHIX | Category Low | Category High | SBHIX % Rank | |
---|---|---|---|---|
Dividend Yield | 0.00% | 0.00% | 6.97% | 37.42% |
Dividend Distribution Analysis
SBHIX | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | Annual | Annually | Annual | Annual |
Net Income Ratio Analysis
SBHIX | Category Low | Category High | SBHIX % Rank | |
---|---|---|---|---|
Net Income Ratio | -0.69% | -2.54% | 1.85% | 80.77% |
Capital Gain Distribution Analysis
SBHIX | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
SBHIX - Fund Manager Analysis
Managers
Robert Stimpson
Start Date
Tenure
Tenure Rank
Jan 18, 2019
3.37
3.4%
Robert D. Stimpson, CFA, CMT. Mr. Stimpson is Co-Chief Investment Officer and a Portfolio Manager at Oak Associates, which he joined in 2001. Prior to joining Oak Associates in 2001, Mr. Stimpson earned an MBA from Emory University. Previously, Mr. Stimpson worked as an Equity Market Analyst for I.D.E.A., ltd and for Merrill Lynch as a Financial Consultant. He has been with the investment industry since 1997. In addition to the CFA designation, Mr. Stimpson holds the CMT charter from the Market Technicians Association.
Tenure Analysis
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.02 | 24.72 | 7.84 | 0.25 |